| Field | Specification |
|---|---|
| Target | |
| Alternative names | Mitogen-activated protein kinase kinase kinase kinase 5; Kinase homologous to SPS1/STE20; KHS; MAPK/ERK kinase kinase kinase 5; MEK kinase kinase 5; MEKKK 5; MAP4K5 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the N-terminus of human MAP4K5, which shares 94.4% amino acid (aa) sequence identity with both mouse and rat MAP4K5. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes mitogen-activated protein kinase kinase kinase kinase 5 (gene MAP4K5) in human samples and is validated for Western blot, IHC and ICC/IF. The predicted molecular weight is 95.0 kDa, and the supplier reports an observed band at about 95 kDa.
MAP4K5 (also called KHS) is a serine/threonine kinase of the germinal-center kinase family. It is thought to respond to environmental stress and to act upstream in the JNK signaling pathway, but its roles are less characterized than those of related MAP4Ks.
| Target | Mitogen-activated protein kinase kinase kinase kinase 5 (gene MAP4K5; UniProt Q9Y4K4, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.01 mg NaN3 |
| Calculated MW | 95.0 kDa |
| Observed MW | 95 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
Samples with a confirmed band (WB): human Jurkat cells, human K562 cells, human HepG2 cells, human HEK293 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human ovarian cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): A431 cells.
Immunogen
Synthetic peptide from the N-terminal region of human MAP4K5. Sequence identity with the mouse and rat orthologs: 94.4%.
Reactivity Notes
The supplier lists reactivity with human. UniProt places mitogen-activated protein kinase kinase kinase kinase 5 in the cytoplasm. Tissue expression noted by UniProt (human): Ubiquitously expressed in all tissues examined, with high levels in the ovary, testis and prostate. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
